323 related articles for article (PubMed ID: 9511177)
21. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Sachse C; Brockmöller J; Bauer S; Roots I
Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
[TBL] [Abstract][Full Text] [Related]
22. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367
[TBL] [Abstract][Full Text] [Related]
23. Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians.
Legrand-Andréoletti M; Stücker I; Marez D; Galais P; Cosme J; Sabbagh N; Spire C; Cenée S; Lafitte JJ; Beaune P; Broly F
Pharmacogenetics; 1998 Feb; 8(1):7-14. PubMed ID: 9511176
[TBL] [Abstract][Full Text] [Related]
24. Alternative reliable method for cytochrome P450 2D6 poor metabolizers genotyping.
Pindurová E; Zourková A; Zrůstová J; Juřica J; Pavelka A
Mol Biotechnol; 2013 Jan; 53(1):29-40. PubMed ID: 22367691
[TBL] [Abstract][Full Text] [Related]
25. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
26. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes.
Dalén P; Dahl ML; Bernal Ruiz ML; Nordin J; Bertilsson L
Clin Pharmacol Ther; 1998 Apr; 63(4):444-52. PubMed ID: 9585799
[TBL] [Abstract][Full Text] [Related]
27. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.
LLerena A; Naranjo ME; Rodrigues-Soares F; Penas-LLedó EM; Fariñas H; Tarazona-Santos E
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1569-83. PubMed ID: 25316321
[TBL] [Abstract][Full Text] [Related]
28. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
29. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.
Schaeffeler E; Schwab M; Eichelbaum M; Zanger UM
Hum Mutat; 2003 Dec; 22(6):476-85. PubMed ID: 14635107
[TBL] [Abstract][Full Text] [Related]
30. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.
Kubota T; Yamaura Y; Ohkawa N; Hara H; Chiba K
Br J Clin Pharmacol; 2000 Jul; 50(1):31-4. PubMed ID: 10886115
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
32. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
33. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine.
Evert B; Griese EU; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 1994 Oct; 350(4):434-9. PubMed ID: 7845481
[TBL] [Abstract][Full Text] [Related]
34. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
35. Correlation between cytochrome P-450 CYP2D6 (CYP2D6) genotype and phenotype.
Chen SQ; Wedlund PJ
Zhongguo Yao Li Xue Bao; 1999 Jul; 20(7):585-8. PubMed ID: 10678117
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses.
Varela N; Quiñones LA; Stojanova J; Garay J; Cáceres D; Cespedes S; Sasso J; Miranda C
Pharmacol Res; 2015 Nov; 101():124-9. PubMed ID: 26211952
[TBL] [Abstract][Full Text] [Related]
37. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
[TBL] [Abstract][Full Text] [Related]
38. PCR-based genotyping for duplicated and deleted CYP2D6 genes.
Johansson I; Lundqvist E; Dahl ML; Ingelman-Sundberg M
Pharmacogenetics; 1996 Aug; 6(4):351-5. PubMed ID: 8873221
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenetics of Cytochrome P450 Enzymes in American Indian and Caucasian Children Admitted to a Psychiatric Hospital.
McGrane IR; Loveland JG
J Child Adolesc Psychopharmacol; 2016 May; 26(4):395-9. PubMed ID: 26871369
[TBL] [Abstract][Full Text] [Related]
40. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles.
Leathart JB; London SJ; Steward A; Adams JD; Idle JR; Daly AK
Pharmacogenetics; 1998 Dec; 8(6):529-41. PubMed ID: 9918137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
